Science 37 Holdings, Inc. SNCE
We take great care to ensure that the data presented and summarized in this overview for Science 37 Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SNCE
Top Purchases
Top Sells
About SNCE
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Insider Transactions at SNCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2024
|
Thermo Fisher Scientific Inc. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,737,980
-100.0%
|
$8,689,900
$5.75 P/Share
|
|
Mar 12
2024
|
Redmile Group, LLC |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,017,203
-100.0%
|
$5,086,015
$5.75 P/Share
|
|
Mar 12
2024
|
Robert C. Faulkner |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,791
-100.0%
|
$133,955
$5.75 P/Share
|
|
Mar 12
2024
|
David Coman Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,781
-100.0%
|
$153,905
$5.75 P/Share
|
|
Mar 12
2024
|
David Coman Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
53,834
-100.0%
|
$269,170
$5.75 P/Share
|
|
Mar 12
2024
|
John W Hubbard |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,050
-100.0%
|
$10,250
$5.75 P/Share
|
|
Mar 12
2024
|
Emily Rollins |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,050
-100.0%
|
$10,250
$5.75 P/Share
|
|
Mar 12
2024
|
Neil Tiwari |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,050
-100.0%
|
$10,250
$5.75 P/Share
|
|
Mar 12
2024
|
Paul Von Autenried |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,302
-100.0%
|
$11,510
$5.75 P/Share
|
|
Mar 12
2024
|
Christine A Pellizzari Chief Legal and HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
35,115
-100.0%
|
$175,575
$5.75 P/Share
|
|
Mar 12
2024
|
Christine A Pellizzari Chief Legal and HR Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,579
-100.0%
|
$72,895
$5.75 P/Share
|
|
Mar 12
2024
|
Mike Zaranek Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,212
-100.0%
|
$111,060
$5.75 P/Share
|
|
Mar 12
2024
|
Mike Zaranek Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,070
-100.0%
|
$45,350
$5.75 P/Share
|
|
Mar 12
2024
|
Darcy Forman Chief Delivery Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,644
-100.0%
|
$123,220
$5.75 P/Share
|
|
Mar 12
2024
|
Darcy Forman Chief Delivery Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,753
-100.0%
|
$78,765
$5.75 P/Share
|
|
Mar 12
2024
|
Jonathan Cotliar Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,864
-100.0%
|
$64,320
$5.75 P/Share
|
|
Mar 12
2024
|
Jonathan Cotliar Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
41,891
-100.0%
|
$209,455
$5.75 P/Share
|
|
Mar 12
2024
|
Michael Shipton Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,247
-100.0%
|
$46,235
$5.75 P/Share
|
|
Mar 10
2024
|
Michael Shipton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,006
-24.53%
|
$15,030
$5.73 P/Share
|
|
Mar 10
2024
|
Michael Shipton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,713
+41.56%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.74M shares |
|---|
| Disposition due to a tender of shares in a change of control transaction | 2.93M shares |
|---|---|
| Sale (or disposition) back to the issuer | 126K shares |
| Payment of exercise price or tax liability | 502K shares |